VRTX 10-K Analysis: Vertex's Hidden Margin Architecture and the Royalty Gamble
Vertex Pharmaceuticals reported $12.0 billion in FY 2025 revenue with an 86.2% gross margin — numbers that suggest a well-oiled biotech machine. But newly disclosed segment data reveals that $1.05 billion of Vertex's $1.65 billion COGS is royalty payments, not manufacturing costs. Strip out the royalties and the real product margin is 95.0%. The problem: Royalty Pharma is now seeking to double the royalty rate on ALYFTREK, Vertex's next-gen CF product — putting $200 million or more in annual EBIT at stake in a company where 98.5% of product revenue comes from cystic fibrosis.